- Home
- TRIB vs VRAX Comparison
TRIB vs VRAX Comparison
Compare TRIB & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- VRAX
- Stock Information
- Founded
- TRIB 1992
- VRAX 2013
- Country
- TRIB Ireland
- VRAX United Kingdom
- Employees
- TRIB N/A
- VRAX N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TRIB Health Care
- VRAX Health Care
- Exchange
- TRIB Nasdaq
- VRAX Nasdaq
- Market Cap
- TRIB 5.4M
- VRAX 4.4M
- IPO Year
- TRIB N/A
- VRAX 2022
- Fundamental
- Price
- TRIB $1.11
- VRAX $0.57
- Analyst Decision
- TRIB
- VRAX Strong Buy
- Analyst Count
- TRIB 0
- VRAX 1
- Target Price
- TRIB N/A
- VRAX $3.00
- AVG Volume (30 Days)
- TRIB 13.5M
- VRAX 1.4M
- Earning Date
- TRIB 11-14-2025
- VRAX 01-01-0001
- Dividend Yield
- TRIB N/A
- VRAX N/A
- EPS Growth
- TRIB N/A
- VRAX N/A
- EPS
- TRIB N/A
- VRAX N/A
- Revenue
- TRIB $61,555,000.00
- VRAX $6,331.00
- Revenue This Year
- TRIB $13.51
- VRAX $217,274.83
- Revenue Next Year
- TRIB $13.14
- VRAX N/A
- P/E Ratio
- TRIB N/A
- VRAX N/A
- Revenue Growth
- TRIB 8.31
- VRAX N/A
- 52 Week Low
- TRIB $0.48
- VRAX $0.52
- 52 Week High
- TRIB $3.44
- VRAX $3.62
- Technical
- Relative Strength Index (RSI)
- TRIB 45.04
- VRAX 31.62
- Support Level
- TRIB $1.42
- VRAX $0.52
- Resistance Level
- TRIB $1.58
- VRAX $0.65
- Average True Range (ATR)
- TRIB 0.15
- VRAX 0.05
- MACD
- TRIB -0.07
- VRAX -0.01
- Stochastic Oscillator
- TRIB 2.80
- VRAX 18.54
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).